Nice's decision to withhold a breakthrough prostate cancer drug is a "cruel twist" as it comes "just days" after a study confirmed its success, campaigners have said.
Prostate Cancer UK called on Nice, who vet the cost effectiveness of medicine for NHS patients, to change its "post-chemo" policy on new drugs.
Enzalutamide is already licensed for those who've had chemotherapy but this trial will hopefully establish a robust base of evidence to demonstrate that it should be available beforehand.
This is good news but sadly won't help the one man an hour who dies of prostate cancer at present.
We need to see drugs like enzalutamide available sooner rather than later, and so it's a cruel twist that this study comes just days after Nice ruled out the drug for men who have already had chemotherapy and the only other drug available at this stage, abiraterone.
More top news
Prince George is not only heir to Britain's throne, but a future long distance runner too, if his uncle has anything to do with it.
A 3-year-old child grabbed his mother's gun from her purse when he went to get her iPhone, police said.
A 350,000 ton landslip in the Harbury area between Leamington Spa and Banbury yesterday is affecting both train services.